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OF BLOOD PLASMA AND ASCETIC FLUID IN PATIENTS  
WITH LIVER CIRRHOSIS
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With the purpose of selection of an individual treatment strategy the author has studied the protein content as well as the chemical 
properties of blood plasma and ascites in patients with liver cirrhosis at different stages of its intensity. 262 patients with liver cirrhosis 
were divided into 4 groups according to the diagnostic examination results which revealed different severity of the pathological process 
in the liver parenchyma . Protein level, total bilirubin content, the average mass molecules, the residual nitrogen, urea, creatinine, ALT,  
AST, alkaline phosphatase, cholesterol and lecithin concentrations were determined in blood plasma and ascites of patients with liver 
cirrhosis . The data obtained reveals the protein homeostasis disturbance, atherogenic lipoproteins level increase, which induce the 
hepatocytes membrane structure failure in patients with liver cirrhosis at all stages . Ascites detected correlated with the liver parenchyma 
degree of the functional activity disturbances . The author concludes that homeostasis disorders revealed in patients with the liver 
cirrhosis, complicated by ascites, should be taken into account in cases of surgical treatment .
Keywords: liver cirrhosis, ascites, proteins, endotoxicosis, pathogenetic treatment, surgical individual treatment tactics.
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Introduction . Treatment of patients 
with liver cirrhosis (LC) and its 
complications remains one of the most 
difficult problems of surgery, including 
the surgical hepatology and biliary 
surgery . According to the WHO, the 
LC rate is steadily increasing [1, 2]. As 
to the results of autopsy, it ranges from 
1 to 11% [3-5].
Unfavorable high incidence of LC 
morbidity as described above (due to 
rising incidence of acute viral hepatitis, 
especially due to viral hepatitis types 
B, C and D) results in marked chronic 
inflammatory and destructive process 
in the liver parenchyma [6, 7] with the 
formation of LC and other complications 
[7, 8].
It should also be noted that 
development of inflammatory and 
destructive lesions of the liver with 
the formation of LC is brought about 
by adverse environmental conditions, 
contact with hepatotropic poisons, 
alcoholism and drug addiction . Viral 
hepatitis play an important part in 
increasing the incidence of LC, as it was 
shown that in patients with viral hepatitis 
B and C the chronic pathological process 
in the liver during the first year can be 
registered in 15-22.7% of cases [2]. As 
the course of viral hepatitis B goes on 
for about 3-5 years - the chronic process 
is observed in 40.9% of patients and in 
74.4% of patients with hepatitis C. It is 
shown that on average 20-30% of these 
patients develop liver cirrhosis, and 
about 20% of the disease is transformed 
into cancer [2, 3, 9].
Therefore, adverse environmental 
conditions, consistently high level of 
alcoholism, drug addiction growth, 
reinforced by economic difficulties, 
promote the growth of the liver 
disease as well as the diseases in 
general organs of the gastro-duodeno-
hepatobiliary system, as it is the leader 
in the maintenance and regulation of 
homeostasis . A severe course of the 
disease, prognosis, and - in most cases 
- failure of treatment makes this disease 
the most important in modern surgery . It 
is clear that specific surgical techniques 
should be used for these patients as well 
as individual approach . On the basis of 
this an individual treatment strategy 
should be devised . Therefore, we made 
a series of retrospective calculations 
and traced the quantitative content 
of blood proteins, and a number of 
other compounds, which determine 
peculiarities of the course of endotoxic 
reactions in blood and ascetic fluid (AF) 
in patients with LC in the comparative 
perspective study .
Objective . Investigation of proteins 
and determination of chemical properties 
of blood plasma and AF in patients with 
LC in different stages of its intensity 
in the comparative perspective study 
in order to select individual tactics of 
further treatment .
Materials and methods. 262 patients 
aged from 36 to 69 with LC have been 
treated during the last 7 years . There were 
164 (62.6%) women and 98 (37.4%) men. 
The age of 67 patients (25.6%) was over 
40, the age of 97 patients (37.0%) was over 
50, and the age of 56 patients (21.4%) was 
over 60.
The LC was diagnosed after 
clinical examination of patients, blood 
chemistry, ultrasound examination of 
the organs of the hepato-pancreato-
duodenal area, CT, endoscopic retrograde 
pancreatocholangiography, etc .
As a result of complex diagnostic 
examination and subsequent treatment, all 
patients were retrospectively divided into 
4 groups: group 1 - patients with LC in 
the compensation stage (n=33, 12.6%), 
group 2 - patients with LC in the sub-
compensation (n=152, 58.0%), group 3 
- patients with LC in the decompensated 
stage (n=61, 23.3%) and group 4 - patients 
with LC in the critical terminal stage (n=16, 
6.1.0%). The control group consisted of 
19 healthy individuals without liver 
disease, having passed a professional 
medical examination.
Conventional methods determined the 
content of proteins (albumin, globulins), 
and total bilirubin, the molecules of 
medial weight (MMW), residual nitrogen, 
urea, creatinine, ALT, AST, alkaline 
phosphatase, cholesterol and lecithin in 
the blood plasma and AF of patients with 
LC . The results obtained in patients at the 
time of admission to the surgical hospital 
before the treatment have been analyzed . 
The results were treated statistically . 
Differences were considered statistically 
significant in p<0.05.
Results and discussion .
The data are presented in the 
tables . When analyzing the quantitative 
characteristics of blood plasma proteins 
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and AF in patients with LC at different 
stages of its manifestation, it was clear 
that the main studied indices did not 
differ significantly from those received 
in the follow-up studies (Table 1, p>0.05) 
in patients of group 1 . So, considering the 
figures, the number of proteins and other 
investigated compounds (Table 2), it is 
clear that the relative compensation of 
its function is a characteristic of patients 
with the first stage of the pathological 
process in the hepatic parenchyma 
in absence of an active destructive 
(alternating) process, which is expressed 
predominantly by maintenance of the 
protein-synthesizing function, but still 
we can observe lipid metabolism disorder 
and moderate chronic intoxication.
Patients with LC at the sub-
compensation stage are characterized 
by moderate activation of the liver with 
clearly decreasing protein-synthesizing 
function, mainly due to albumin-globulin 
imbalance (Table 1), with development of 
chronic intoxication. AF of these patients 
is characterized by protein reduction, and 
decrease in plasma results in significantly 
greater loss of its concentration in the 
blood due to extravasation. The content 
of toxic compounds (bilirubin, nitrogen-
containing components) had a tendency 
to increase, but was statistically identical 
with the corresponding data of healthy 
patients .
61 patients with LC in the 
decompensated stage clearly showed 
dysproteinemia . In general, deep 
dysfunction of the liver accompanied 
by the development of cholestasis and 
cytolysis, hypo- and dysproteinemia, 
nitrogen- and fermentemia, etc . is 
natural for this group of patients (Tables 
1 and 2). AF in these patients was 
characterized by protein reduction – by 
almost 2.5-3.0 times (p <0.01). So this 
is the consequence of protein-synthetic 
disorder of the liver .
Data on disorder of homeostasis 
of cholesterol and the related lipid-
containing components are of interest 
as their concentration has increased 
in the patients of the 3rd examined 
group. We can explain this by the fact 
that accumulation of low-density and 
very low density lipoproteins that are 
responsible for removing cholesterol 
from the membrane causes the 
development of destructive changes in 
the hepatocyte membrane, which is the 
pathophysiological basis for further 
progression of the pathological process 
in LC . It is likely that one of the possible 
directions of pathogenetically grounded 
therapy in patients with LC is the use of 
hypolipid therapy .
Another interesting aspect that 
can be seen in Tables 1 and 2 is the 
content of the studied compounds in 
AF of patients with LC . Thus, the same 
components of the body homeostasis 
can be found in AF, such as the blood 
plasma (sometimes even in greater 
volume), making AF an adequate plasma 
component replacement under LC and 
its progression to liver failure . Having a 
significant antiatherogenic potential AF 
should be determined before the certain 
repeated complex of hypolipid therapy.
Hypo- and dysproteinemia were 
marked in the blood of 16 patients in the 
terminal stage of the disease . The protein 
content in AF was also significantly 
lower . The following clinical symptoms 
were predominant during the examination 
of such patients: development of edema 
of the lower extremities, cachexia, 
severe cardiovascular and pulmonary 
insufficiency, presence of transsudate in 
the pleural cavity, etc .
Summarizing the data, it should be 
noted that all stages of LC, which are 
complicated by the presence of ascites, 
are characterized by the disorder of 
protein homeostasis, increased content 
of atherogenic lipoproteins in the blood 
and consequent changes in the structure 
of hepatocyte membranes . The studied 
key indices of AF correlated (r=0.69-
0.87) with the degree of functional 
activity of the liver parenchyma . The 
above indices of disturbed homeostasis 
of the corresponding patients should be 
taken into account when developing the 
surgical treatment strategies for patients 
with LC complicated by ascites .
Tab. 1. 
Quantitative characteristic of blood plasma proteins and ascetic fluid (АF)  
in patients with liver cirrhosis in different stages of its manifestation
Manifestation 
stage of liver 
cirrhosis in 
treated patients
Site of 
determination
General concentration, g/l 
M±m
Ratio of 
albumin / 
globulinGeneral
protein Albumins
Globulins
Alpha Beta Gamma
1 2
Control indices (blood plasma), 
n=19 77.7±7.3 48.2±5.6 4.5±0.4 6.5±0.5 12.7±1.4 14.1±1.6 1.4±0.1
І stage,
n=33
Blood plasma 62.9±6.9 34.8±4.1 6.8±0.9 10.7±1.3 11.3±1.5 19.4±2.0 1.0
АF 44.6±4.5 33.8±3.6 - - - - -
ІІ stage, n=152
Blood plasma 57.1±4.9 28.9±3.2 5.2±0.7 11.3±1.4 12.7±1.7 22.1±2.3 0.9
АF 31.1±2.9 21.9±2.4 - - - - -
ІІІ stage, n=61
Blood plasma 54.7±5.0 20.4±2.4 4.6±0.5 8.9±0.8 12.9±1.7 23.5±2.4 0.8
АF 19,7±2,3 - - - - - -
ІV stage,
n= 16
Blood plasma 43.7±4.4 18.3±2.1 5.2±0.5 8.6±0.8 13.1±1.7 30.6±3.1 0.6
АF 3.1±0.4 - - - - - -
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Tab. 2. 
Comparative characteristic of chemical properties of blood plasma and ascetic fluid (АF)  
in patients with liver cirrhosis in different stages of its manifestation
Manifestation 
stage of liver 
cirrhosis 
in treated 
patients
Site of 
determination
Total 
bilirubin, 
mcmol/l
МСМ, 
(од)
Residual 
nitrogen, 
mmol/l
Urea, 
mmol/l
Creatinine, 
mmol/l
ALT, 
mcmol/l
AST, 
mcmol/l
Alkaline 
phosphatase, 
U/l
Cholesterol, 
mmol/l
Lecithin, 
mmol/l
Control indices  
(blood plasma), n=19 15.6±3.3 208±20 16.5±1.8 5.1±0.6 0.08±0.01 0.56±0.04 0.34±0.03 44.7±4.1 5.1±0.5 1.7±0.2
І stage, n=152
Blood plasma 18.6±2.2 245±25 18.1±1,9 5.1±0.5 0.06±0.01 0.26±0.02 0.30±0.02 62.1±5.7 4.4±0.3 1.4±0.1
АF 5.9±0.6 90±8 6.7±0.7 2.1±0.2 - 0.19±0.02 0.16±0.02 - 3.0±0.3 1.0±0.1
ІІ stage, n=152
Blood plasma 33.7±3.4 300±29 26.4±2.3 5.5±0.5 0.08±0.01 0.62±0.05 0.91±0.08 69.8±7.1 3.7±0.4 5.0±0.4
АF 18,.1.2.1 210±19 21.1±2.0 3.0±0.3 - 0.24±0.02 0.21±0.02 - 2,4±0.3 0.7±0.1
ІІІ stage, n=61
Blood plasma 89.4±8.8 600±56 36.7±3.2 9.1±0.8 1.00±0.01 0.56±0.06 0.54±0.05 104.4±9.3 7.6±0.7 3.1±0.2
АF 38.4±4.1 390±40 26.4±2.9 5.9±0.5 - 0.45±0.04 0.31±0.03 - 3.6±0.3 0.8±0.1
ІV stage,
n= 16
Blood plasma 15.1±1.3 - 21.4±2.2 7.3±0.7 0.07±0.01 0.23±0.02 0.37±0.04 109±9.7 3.1±0.3 2.2±0.2
АF 9.1±0.8 - 17.8±1.8 4.6±0.4 - 0.21±0.02 0.16±0.02 - 3.0±0.3 0.6±0.1
